Stability challenges of oncological medicines: The overlooked role of industrial pharmacy
- 6 April 2026
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Abstract
Background: Ensuring the stability and quality of oncological medicines remains a major challenge across both industrial and hospital settings. These products are often biologics or highly sensitive compounds are vulnerable to chemical, physical, and microbiological degradation pathways that can compromise therapeutic efficacy and patient safety. Objective: This review provides an overview of the main stability challenges associated with oncological medicines and highlights the complementary roles of industrial pharmacy and hospital pharmacy in preventing degradation, contamination, and handling-related risks. Discussion: Chemical degradation mechanisms including oxidation, deamidation, acylation, and photo-induced reactions are particularly prominent in peptides, monoclonal antibodies, and antibody–drug conjugates. Physical instability, driven by temperature fluctuations or hydrophobic payloads in ADCs (, can promote aggregation and reduce shelf-life. Microbiological instability remains a critical concern, especially in immunocompromised patients, and underscores the importance of controlled environments, aseptic technique, and compliance with sterility and endotoxin standards. Contamination risks particulate, microbiological, or cross-contamination are markedly lower when oncological medicines are prepared in ISO-classified clean rooms, isolators, or closed-system transfer devices (CSTDs). Post-reconstitution stability is equally dependent on strict cold-chain management, appropriate conditioning, and optimized clinical workflows. Robotic compounding systems further enhance safety by improving precision, reducing environmental exposure, and strengthening traceability. Conclusion: Stability preservation for oncological medicines requires an integrated approach that bridges industrial formulation strategies, advanced manufacturing technologies, and rigorously controlled hospital practices. Strengthening the collaboration between industry and clinical pharmacy is essential to ensure the quality, safety, and therapeutic performance of anticancer treatments.Keywords
This publication has 32 references indexed in Scilit:
- Molecular mechanisms for stabilizing biologics in the solid stateJournal of Pharmaceutical Sciences, 2024
- Stability assessment of Polatuzumab vedotin and Brentuximab vedotin using different analytical techniquesJournal of Pharmaceutical and Biomedical Analysis, 2023
- Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and EfficacyJournal of Pharmaceutical Sciences, 2022
- Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for BiologicsPharmaceutical Research, 2021
- Chemical and physical instabilities in manufacturing and storage of therapeutic proteinsCurrent Opinion in Biotechnology, 2019
- The impact of cancer drug wastage on economic evaluationsCancer, 2017
- Médicaments du cancer : quelles innovations et à quel prix ?Bulletin du Cancer, 2016
- Potential Risks of Pharmacy CompoundingDrugs in R&D, 2013
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Guidelines for the practical stability studies of anticancer drugs: A European consensus conferenceAnnales Pharmaceutiques Françaises, 2011